From: Enhancer alterations in cancer: a source for a cell identity crisis
Cancer type(s) | Mutation | Reference(s) |
---|---|---|
Burkitt’s lymphoma | IGH/MYC translocation | [109] |
Melanoma, central nervous system, bladder, thyroid | TERT promoter | |
Breast, prostate | FOXA1 | |
AML, myelodysplastic syndromes | GATA2 | [123] |
Breast, lung | GATA3 | |
AML, breast, urothelial | RUNX1 | |
Bladder, head and neck, lung, urothelial, breast | MLL2/MLL3/MLL4 | |
B-cell lymphoma, lung | EZH2 | |
AML, lung | DNMT3A | |
AML, bladder, lung, urothelial | TET2 | |
Urothelial, bladder, breast, head and neck | CTCF | |
Bladder, glioblastoma, lung, urothelial | STAG2 | |
Bladder, urothelial, AML | SMC1A | |
Bladder, AML, lung | SMC3 | |
Lung, AML | RAD21 | |
Transitional cell carcinoma | NIPBL | [135] |
Prostate, adrenocortical, uterine leiomyoma | MED12 |